Summary
Recent results have indicated that the 5-HT1A receptor subtype mediates the adrenaline-releasing and hyperglycemic effects of 8-hydroxy-2-(di-n-propylamino)tetralin in the rat. The aim of this study was to analyse, by means of the peripherally acting 5-HT1A receptor agonist, N,N-dipropyl-5-carboxamidotryptamine (DP-5-CT), whether these 5-HT1A receptors are peripherally or centrally localised. In view of the appreciable affinity of DP-5-CT for the 5-HT1D receptor subtype, the effects of the mixed 5-HT1B/5-HT1D receptor agonist 7-trifluoromethyl-4-(4-methyl-1-piperazinyl)-pyrrolo(1,2-a)quinoxaline (CGS 1206613), and the mixed 5-HT1A5-HT1B/5-HT1D receptor agonist 5-methoxy-3(1,2,3,6-tetrahydropyridine-4-yl)1H-indole (RU 24969) were also investigated.
Administration of DP-5-CT (0.3 and 1 mg/kg i. v.) increased plasma glucose levels dose-dependently, whereas only the 1 mg/kg dose of DP-5-CT elicited a rise in plasma adrenaline levels. In contrast, CGS 1206613(1.5 and 4.5 mg/kg 1. v.) did not affect either plasma adrenaline or plasma glucose levels. Administration of RU 24969 (0.5–4.5 mg/kg i. v.) increased dose-dependently both plasma adrenaline and glucose levels. The data suggest that central 5-HT1A receptors, but neither 5-HT1B nor 5-HT1D receptors, regulate plasma adrenaline and glucose levels.
Similar content being viewed by others
References
Anton AH, Sayre DF (1962) A study of the factors affecting the aluminum oxide-trihydroxyindole procedure for the analysis of catecholamines. J Pharmacol Exp Ther 138:360–375
Bagdy G, Szemeredi K, Murphy DL (1989) Marked increases in plasma catecholamine concentrations precede hypotension and bradycardia caused by 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) in conscious rats. J Pharm Pharmacol 41:270–272
Chaouloff F, Jeanrenaud B (1987) 5-HT1A and alpha 2-adrenergic receptors mediate the hyperglycemic and hypoinsulinemic effects of 8-hydroxy-2-(di-n-propylamino)tetralin in the conscious rat. J Pharmacol Exp Ther 243:1159–1166
Chaouloff F, Jeanrenaud B (1988) Hyperinsulinemia of the genetically obese (fa/fa) rat is decreased by a low dose of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). Eur J Pharmacol 147:111–118
Chaouloff F, Baudrie V, Laude D (1990a) Evidence that the 5-HT1A receptor agonists buspirone and ipsapirone activate adrenaline release in the conscious rat. Eur J Pharmacol 177:107–110
Chaouloff F, Baudrie V, Laude D (1990b) Evidence that 5-HT1A receptors are involved in the adrenaline-releasing effects of 8-OH-DPAT in the conscious rat. Naunyn-Schmiedeberg's Arch Pharmacol 341:381–384
Chaouloff F, Baudrie V, Laude D (1990c) Adrenaline-releasing effects of the 5-HT1A receptor agonists 8-OH-DPAT, buspirone, and ipsapirone in the conscious rat. Br J Pharmacol (Proc Br Pharmacol Sci) (in press)
Chaouloff F, Baudrie V, Laude D (1990d) Pentobarbital anaesthesia prevents the adrenaline-releasing effect of the 5-HT1A receptor agonist 8-OH-DPAT. Eur J Pharmacol 180:175–178
Chaouloff F, Laude D, Baudrie V (1990e) Ganglionic transmission is a prerequisite for the adrenaline-releasing and hyperglycemic effects of 8-OH-DPAT. Eur J Pharmacol (in press)
Doods HN, Bodeke HWGM, Kalkman HO, Hoyer D, Mathy M-J, van Zwieten PA (1988) Central 5-HT1A receptors and the mechanism of the central hypotensive effect of (+)8-OH-DPAT; DP-5-CT, R28935, and urapidil. J Cardiovasc Pharmacol 11:432–437
Euvrard C, Boissier JR (1980) Biochemical assessment of the central 5-HT agonist activity of RU 24969 (a piperidinyl indole). Eur J Pharmacol 63:65–72
Fozard JR, Mir AK, Middlemiss DN (1987) Cardiovascular response to 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) in the rat: site of action and pharmacological analysis. J Cardiovase Pharmacol 9:328–347
Hoyer D (1988) Functional correlates of serotonin 5-HT1 recognition sites. J Receptor Res 8:59–81
Markstein R, Hoyer D, Engel G (1986) 5-HT1A receptors mediate stimulation of adenylate cyclase in rat hippocampus. Naunyn-Schmiedeberg's Arch Pharmacol 333:335–341
Middlemiss DN, Fozard JR (1983) 8-hydroxy-2-(di-n-propylamino)tetralin discriminates between subtypes of the 5-HT1 recognition site. Eur J Pharmacol 90:151–153
Mir AK, Hibert M, Fozard JR (1987) Cardiovascular effects of N,N-dipropyl-5-carboxamidotryptamine, a potent and selective 5-HT1A receptor ligand. In: Nobin A, Owman C, Arneklo-Nobin B (eds) Neuronal messengers in vascular function. Elsevier, New York, pp 21–29
Molderings GJ, Fink K, Schlicker E, Göthert M (1987) Inhibition of noradrenaline release via presynaptic 5-HT1B receptors of the vena cava. Naunyn-Schmiedeberg's Arch Pharmacol 336:245–250
Nahorski SR, Willcocks AL (1983) Interactions of beta-adrenoceptor antagonists with 5-hydroxytryptamine receptor subtypes in rat cerebral cortex. Br J Pharmacol 78:107P
Neale RF, Fallon SL, Boyar WC, Wasley JWF, Martin LL, Stone GA, Glaeser BS, Sinton CM, Williams M (1987) Biochemical and pharmacological characterization of CGS 12066B, a selective serotonin-1B agonist. Eur J Pharmacol 136:1–9
Peroutka SJ (1985) Selective interaction of novel anxiolytics with 5-hydroxytryptamine1A receptors. Biol Psychiatry 20:971–978
Schmidt AW, Peroutka SJ (1989) 5-hydroxytryptamine receptor “families”. FASEB J 3:2242–2249
Schoeffter P, Hoyer D (1989) Interaction of arylpiperazines with 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors: do discriminatory 5-HT1B receptor ligands exist? Naunyn-Schmiedeberg's Arch Pharmacol 339:675–683
Author information
Authors and Affiliations
Additional information
Send offprint requests to F. Chaouloff at the above address
Rights and permissions
About this article
Cite this article
Laude, D., Baudrie, V., Martin, G.R. et al. Effects of the 5-HT1 receptor agonists DP-5-CT, CGS 12066B, and RU 24969 on plasma adrenaline and glucose levels in the rat. Naunyn-Schmiedeberg's Arch Pharmacol 342, 378–381 (1990). https://doi.org/10.1007/BF00169452
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00169452